Manufacturer Requested Reimbursement Criteria1:
Tysabri SC to be funded in similar manner as Tysabri IV.
Tysabri (intravenous, IV; and subcutaneous, SC) is indicated as monotherapy for the treatment of patients with the relapsing-remitting form of multiple sclerosis (MS) to reduce the frequency of clinical exacerbations, to decrease the number and volume of active brain lesions identified on magnetic resonance imaging (MRI) scans and to delay the progression of physical disability. Tysabri is generally recommended in MS patients who have had an inadequate response to, or are unable to tolerate, other therapies for multiple sclerosis.
|Call for patient/clinician input open||23-Mar-21|
|Call for patient/clinician input closed||14-May-21|
- Patient input submission received from Multiple Sclerosis Society of Canada
- Submission temporarily suspended
- Voluntarily withdrawn by the sponsor on 21-Apr-2022
Last Updated : April 21, 2022